CLINICAL TRIALS PROFILE FOR KW-6356
✉ Email this page to a colleague
Clinical Trials for KW-6356
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02939391 ↗ | A Study of KW-6356 in Subjects With Early Parkinson's Disease | Completed | Kyowa Hakko Kirin Company, Limited | Phase 2 | The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score between KW-6356 and placebo in subjects with early Parkinson's disease in Japan. |
NCT02939391 ↗ | A Study of KW-6356 in Subjects With Early Parkinson's Disease | Completed | Kyowa Kirin Co., Ltd. | Phase 2 | The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score between KW-6356 and placebo in subjects with early Parkinson's disease in Japan. |
NCT03703570 ↗ | A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations | Completed | Kyowa Hakko Kirin Co., Ltd | Phase 2 | The primary objective of this study is to determine the recommended dose and evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) partIII score between KW-6356 and placebo in patients with Parkinson's disease on treatment with Levodopa-containing preparations as an adjunctive therapy. |
NCT03703570 ↗ | A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations | Completed | Kyowa Kirin Co., Ltd. | Phase 2 | The primary objective of this study is to determine the recommended dose and evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) partIII score between KW-6356 and placebo in patients with Parkinson's disease on treatment with Levodopa-containing preparations as an adjunctive therapy. |
NCT03830528 ↗ | A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects | Completed | Kyowa Hakko Kirin Co., Ltd | Phase 1 | Phase I study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of KW-6356 in healthy volunteers |
NCT03830528 ↗ | A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects | Completed | Kyowa Kirin Co., Ltd. | Phase 1 | Phase I study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of KW-6356 in healthy volunteers |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for KW-6356
Condition Name
Clinical Trial Locations for KW-6356
Trials by Country
Clinical Trial Progress for KW-6356
Clinical Trial Phase
Clinical Trial Sponsors for KW-6356
Sponsor Name